SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second quarter and six-month periods ended January 31, 2009.
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second quarter and six-month periods ended January 31, 2009.
